-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Guolong Pharmaceutical Receives Approval for Upadacitinib API
Category:
发布时间：2026-03-30
【概要描述】
On March 30, the upadacitinib API developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, successfully changed its registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as an API for use in marketed dosage forms. This marks the eighth specialized API product approved by the Group this year.
On March 30, the upadacitinib API developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, successfully changed its registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as an API intended for use in marketed dosage forms. This marks the eighth new specialty API product approved by the Group this year.
According to available information, upadacitinib is a JAK-1 inhibitor indicated for the treatment of rheumatoid arthritis and Crohn’s disease, as well as atopic dermatitis, psoriatic arthritis, ulcerative colitis, giant cell arteritis, and other conditions.
In recent years, the Group has continuously deepened its innovative “API + Formulation” strategy, and to date it boasts 99 API products, including 45 under China Dragon Pharmaceutical. The proportion of specialty APIs has been steadily increasing, with products covering multiple therapeutic areas such as cardiovascular, anti-infective, neurological, and immunological indications, thereby continuously injecting new momentum into the Group’s integrated development of APIs and formulations.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091